Payment overview · 2025
General Payments
$1,502.81
63 reported records · 16 companies
Healthcare provider profile · identity verified
Brian Harris Stiefel, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MARION, VA · NPI 1972565265
Verified facts
What the public records show
CMS Open Payments records show Brian Harris Stiefel, M.D. received $1,502.81 in general payments during 2025 across 63 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $436.62 | 29.1% | 13 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $191.69 | 12.8% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $190.28 | 12.7% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $162.87 | 10.8% | 11 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $96.17 | 6.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $68.02 | 4.5% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $66.72 | 4.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.51 | 4.1% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $56.94 | 3.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.03 | 3.1% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.13 | 1.8% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.16 | 1.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.86 | 1.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.19 | 1.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.22 | 1.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.40 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,502.81 | 63 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $268.30 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $257.00 | 14 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $191.69 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $162.87 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $111.92 | 7 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $96.17 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $56.94 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $56.40 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $47.03 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $46.94 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $27.13 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 70 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 199 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 152 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
70 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
152 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
70 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
199 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 554 | 70 |
| Omeprazole | Omeprazole | 530 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 491 | 86 |
| Atorvastatin Calcium | Atorvastatin Calcium | 473 | 93 |
| Gabapentin | Gabapentin | 459 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 395 | 65 |
| Lisinopril | Lisinopril | 362 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 362 | 72 |
| Famotidine | Famotidine | 306 | 70 |
| Metformin Hcl | Metformin Hcl | 301 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 279 | 54 |
| Furosemide | Furosemide | 263 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 243 | 46 |
| Enalapril Maleate | Enalapril Maleate | 240 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 235 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 227 | 44 |
| Alprazolam | Alprazolam | 222 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 218 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 204 | 24 |
| Allopurinol | Allopurinol | 200 | 36 |
| Ozempic | Semaglutide | 199 | 32 |
| Simvastatin | Simvastatin | 190 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 186 | 44 |
| Prednisone | Prednisone | 183 | 83 |
| Sertraline Hcl | Sertraline Hcl | 181 | 35 |
| Potassium Chloride | Potassium Chloride | 178 | 28 |
| Meloxicam | Meloxicam | 169 | 50 |
| Trazodone Hcl | Trazodone Hcl | 165 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 152 | 27 |
| Losartan Potassium | Losartan Potassium | 151 | 31 |
| Eliquis | Apixaban | 146 | 28 |
| Montelukast Sodium | Montelukast Sodium | 144 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 141 | 33 |
| Valsartan | Valsartan | 138 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 130 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 118 | 26 |
| Tramadol Hcl | Tramadol Hcl | 118 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 112 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 22 |
| Cefuroxime | Cefuroxime Axetil | 110 | 78 |
| Mirtazapine | Mirtazapine | 110 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 110 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 108 | 16 |
| Carvedilol | Carvedilol | 107 | 24 |
| Amoxicillin | Amoxicillin | 100 | 71 |
| Pregabalin | Pregabalin | 100 | 16 |
| Ondansetron Odt | Ondansetron | 98 | 39 |
| Lorazepam | Lorazepam | 96 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 94 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 90 | 15 |
| Levetiracetam | Levetiracetam | 89 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 88 | 14 |
| Clonazepam | Clonazepam | 87 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 87 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 12 |
| Xarelto | Rivaroxaban | 84 | suppressed |
| Atenolol | Atenolol | 81 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 80 | 21 |
| Donepezil Hcl | Donepezil Hcl | 80 | suppressed |
| Diazepam | Diazepam | 78 | 15 |
| Baclofen | Baclofen | 76 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 70 | 11 |
| Mounjaro | Tirzepatide | 70 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 69 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 69 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 68 | 38 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 67 | 55 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 12 |
| Spironolactone | Spironolactone | 65 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 63 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 63 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 11 |
| Sucralfate | Sucralfate | 60 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 26 |
| Symbicort | Budesonide/Formoterol Fumarate | 58 | 13 |
| Folic Acid | Folic Acid | 53 | suppressed |
| Nitroglycerin | Nitroglycerin | 53 | 37 |
| Nystatin | Nystatin | 53 | 36 |
| Ibuprofen | Ibuprofen | 52 | 14 |
| Benazepril Hcl | Benazepril Hcl | 51 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 51 | suppressed |
| Glipizide | Glipizide | 50 | suppressed |
| Januvia | Sitagliptin Phosphate | 50 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 50 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 48 | 14 |
| Temazepam | Temazepam | 45 | suppressed |
| Azithromycin | Azithromycin | 44 | 41 |
| Meclizine Hcl | Meclizine Hcl | 43 | suppressed |
| Topiramate | Topiramate | 42 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Olanzapine | Olanzapine | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Levofloxacin | Levofloxacin | 36 | 30 |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 32 | suppressed |
| Fluconazole | Fluconazole | 30 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 25 |
| Linzess | Linaclotide | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Cilostazol | Cilostazol | 24 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 24 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 22 | 16 |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Phenytoin | Phenytoin | 17 | suppressed |
| Probenecid | Probenecid | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Roflumilast | Roflumilast | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Norethindrone Acetate | Norethindrone Acetate | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,502.81 · 63 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, HETLIOZ, JARDIANCE, Ohtuvayre, Ozempic, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, WATCHMAN Access System, Wegovy, XIFAXAN | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error